Systematically mediastinal lymph node dissection or not in clinical stage T1 ground-glass dominated invasive lung adenocarcinoma: a multi-center, prospective clinical trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036680

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-11-02

Completion date

Unknown

Last updated

2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

experimental group:Systematically mediastinal lymph node dissection

control group: No systematically mediastinal lymph node dissection

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Patients who have signed the informed consent form. 2) A single lesion detected on computed tomography (CT) scan featured as ground glass nodule(GGO) and C/T ratio <= 0.5; 3) Lesion staged as clinical T1N0M0 and resectable by surgery; 4) Histologically confirmed primary invasive lung adenocarcinoma preoperatively or intraoperatively.

Exclusion criteria

Exclusion criteria: 1) Lesion is not resectable by surgery; 2) Patients who had history of other malignant tumors; 2) Patients who had received thoracic surgery; 5) Patients had history of radiation or chemotherapy for thoracic region.

Design outcomes

Primary

Measure	Time frame
Disease free survival;	—

Secondary

Measure	Time frame
complication;	—

Countries

China

Contacts

Public ContactChen Haiquan

hqchen1@yahoo.com+86 021-64175590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026